DSM snags project to feed Australian biologics plant
The custom manufacturing and technology business of Royal DSM has a deal for process development and manufacture of the lead recombinant human protein from Paranta Biosciences of Melbourne, Australia. Terms of the deal were not disclosed, but DSM said much of the work would be handled through the Brisbane facility, a project it refers to as its "blueprint for the biologics plant of the future."
Karen King, president of DSM Biologics, has said the $65 million plant is slated to open in the middle of next year. The plant is getting support from the governments of Queensland and the Commonwealth. It is part of the government's $345 million Translational Research Institute being built to attract medical research to Australia. DSM already has an R&D facility and biologics manufacturing operation in Groningen, Netherlands.
Earlier this month, DSM said it was partnering with Almac to make active pharmaceutical ingredients using both of their enzyme platform technologies. The idea is to pair Almac's expertise in "rapid enzyme identification, scale-up and implementation into early-phase projects" with DSM's "track record of over 30 commercial manufacturing bioprocesses run on a multi-ton scale."